Improving health is one of the toughest challenges facing the world today. As a global, innovation-driven biopharmaceutical company, AstraZeneca has a key contribution to make through the discovery, development, manufacturing and commercialisation of medicines for six important areas of healthcare: cancer, cardiovascular, gastrointestinal, infection, neuroscience and respiratory and inflammation.

AstraZeneca Egypt is engaged in the manufacture and supply of medicines that aim to make a real difference to the lives of Egyptians. Our business is driven by our mission to bring new innovative medicines into peoples’ lives. We are committed to working collaboratively, creatively, and with courage to achieve our goal of better health for patients:

     For patient and the healthcare community, we provide medicines for some of the world’s most serious illnesses, and we aim to provide assistance to enhance medical practice.
     For our employees, we provide a culture in which they feel appreciated, energised and rewarded for their contribution.
    For our stakeholders, we aim to deliver value through our continued focus on innovation and by running our business efficiently.
    For the wider community, we strive to be valued for the contribution our medicines make to society and trusted for the way in which we do business.

AstraZeneca has a solid presence in the Egyptian pharmaceutical market since 1968, when Astra opened its first office, followed by Zeneca Scientific in 1972. Today, AstraZeneca Egypt has around 400 employees, including the commercial operations and the manufacturing facility.

The AstraZeneca Egypt manufacturing facility is located in Sixth of October City. Inaugurated in 2006, the factory has the capacity to produce 400 million tablets and is currently operating 3 packing lines.


Product Generic name Therapy area
Arimidex anastrozole Oncology
Atacand candesartan cilexetil Cardiovascular
Bambec bambuterol Respiratory
Casodex bicalutamide Oncology
Crestor rosuvastatin Cardiovascular
Diprivan propofol Neuroscience
Emla cream lidocaine+prilocaine Local anesthetic
Faslodex fulvestrant Oncology
Imdur isosorbide-5-mononitrate Cardiovascular
Inderal propranolol hydrochloride Cardiovascular
Logimax felodipine - ramipril Gastrointestinal
Losec omeprazole Local anesthetic
Marcaine bupivacaine HCl Infection
Meronem meropenem Gastrointestinal
Nexium esomeprazole Gastrointestinal
Nolvadex tamoxifen citrate Oncology
Plendil felodipine Cardiovascular
Pulmicort budesonide Respiratory
Rhinocort budesonide Respiratory
Seroquel IR quetiapine Neuroscience
Symbicort budesonide - formoterol Respiratory
Tenoret atetonol – chlorothalidone Cardiovascular
Tenoretic atenolol - chlorothalidone Cardiovascular
Tenormin atenolol Cardiovascular
Zestril lisinopril dihydrate Cardiovascular
Zestoretic lisinopril – hydrochlorothiazide Cardiovascular
Zoladex goserelin acetate Oncology
Zomig zolmitriptan Neuroscience
Xylocaine Lidocaine Local anesthetic

Adverse event reporting

In order to monitor the safety of AstraZeneca products, we encourage reporting any side effects experienced while taking an AstraZeneca product.

Phone: +20 2 25980205
Fax: +20 2 5980225


Interested in joining us?

Please send your application to the following e-mail address:


133, Road 90 North
5th Settlement
New Cairo
+20 2 2598 0222
+20 109 0011870